Eversense® Non-adjunctive Use Post Approval Study
Public ClinicalTrials.gov record NCT04836546. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Post Approval Study to Evaluate the Safety and Effectiveness of the Eversense® Continuous Glucose Monitoring (CGM) System Used Non-adjunctively
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a non-blinded, prospective, multi-center, single arm longitudinal cohort study (patient serving as their own control), to evaluate the effectiveness of diabetes with the Eversense CGM System non-adjunctively compared to self-monitoring of blood glucose (SMBG) using a blood glucose (BG) meter in participants with either Type 1 or Type 2 diabetes. Subjects will serve as their own control, with their baseline based on using SMBG to manage their diabetes for the first 6 months followed by using Eversense CGM System non-adjunctively for the second 6 months. Total follow-up duration is 12 months. The investigation will include both clinic visits and home use of Eversense CGM System. The nonadjunctive phase will have two sensors, up to 90-day duration, inserted sequentially. All care decisions specific to diabetes will be based on blood glucose (BG) values in the first phase and the Eversense CGM system values in the second phase.
Study identification
- NCT ID
- NCT04836546
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 925 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 13, 2021 (Actual)
- Primary completion
- Mar 31, 2026 (Estimated)
- Completion
- Mar 31, 2026 (Estimated)
- Last update posted
- Aug 13, 2025
2021 – 2026
United States locations
- U.S. sites
- 23
- U.S. states
- 16
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| LA Universal Research Center, Inc. | Los Angeles | California | 90057 | — |
| Denver Endocrinology, Diabetes & Thyroid Center | Englewood | Colorado | 80113 | — |
| CMR of Greater New Haven | Hamden | Connecticut | 06517 | — |
| Chase Medical Research | Waterbury | Connecticut | 06708 | — |
| The Center for Diabetes and Endocrine Care | Fort Lauderdale | Florida | 33312 | — |
| MedCare Research | Miami | Florida | 33165 | — |
| Miami Lakes Clinical Trials INC | Miami Lakes | Florida | 33014 | — |
| Atlanta Diabetes Associates | Atlanta | Georgia | 30318 | — |
| Rocky Mountain Clinical Research | Idaho Falls | Idaho | 83404 | — |
| Springfield Clinic | Springfield | Illinois | 62702 | — |
| Tandem Clinical Research | Marrero | Louisiana | 70072 | — |
| Southern Maryland Medical Group | Camp Springs | Maryland | 20746 | — |
| Metro Detroit Endocrinology | Dearborn | Michigan | 48126 | — |
| Diabetes and Endocinology Specialists, Inc. | Chesterfield | Missouri | 63017 | — |
| Endocrine Associates of West Village | Long Island City | New York | 11101 | — |
| Physician's East Endocrinology | Greenville | North Carolina | 27834 | — |
| Superior Clinical Research | Smithfield | North Carolina | 27577 | — |
| AM Diabetes & Endocrinology | Bartlett | Tennessee | 38133 | — |
| Texas Diabetes and Endocrinology | Austin | Texas | 78749 | — |
| Southwest Family Medicine Associates | Dallas | Texas | 75235 | — |
| Clinical Research Solution Institute | Houston | Texas | 77095 | — |
| RGV Endocrine Center | McAllen | Texas | 78503 | — |
| Green Mountain Research Institute | Rutland | Vermont | 05701 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04836546, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 13, 2025 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04836546 live on ClinicalTrials.gov.